Glycoprotein metabolism disease
MONDO:0045010A disease that has its basis in the disruption of glycoprotein metabolic process.
Also known as: disorder of glycoprotein metabolic process, disorder of glycoprotein metabolism, glycoprotein metabolic process disease, glycoprotein metabolism disease
23 clinical trials for this condition and its sub-types, 1 tagged with Glycoprotein metabolism disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Glycoprotein metabolism disease
-
Disorder of protein O-glycosylation 0 trials · 13 incl. sub-types
6 sub-types
- Myopathy caused by variation in FKRP 0 trials · 8 incl. sub-types Sub-types →
- Qualitative or quantitative defects of protein involved in O-glycosylation of alpha-dystroglycan 0 trials · 8 incl. sub-types Sub-types →
- Disorder of fucoglycosan synthesis 0 trials · 4 incl. sub-types Sub-types →
- Autosomal recessive limb-girdle muscular dystrophy type 2R1 1 trial
- Myopathy caused by variation in POMGNT1 0 trials · 1 incl. sub-types Sub-types →
- Myopathy caused by variation in POMGNT2 0 trials Sub-types →
-
Disorder of protein N-glycosylation 0 trials · 7 incl. sub-types
26 sub-types
- PMM2-congenital disorder of glycosylation 5 trials
- MPI-congenital disorder of glycosylation 1 trial
- PGM1-congenital disorder of glycosylation 1 trial
- ALG1-congenital disorder of glycosylation 0 trials
- ALG11-congenital disorder of glycosylation 0 trials
- ALG12-congenital disorder of glycosylation 0 trials
- ALG2-congenital disorder of glycosylation 0 trials Sub-types →
- ALG3-congenital disorder of glycosylation 0 trials
- ALG6-congenital disorder of glycosylation 1C 0 trials
- ALG8-congenital disorder of glycosylation 0 trials
- ALG9-congenital disorder of glycosylation 0 trials Sub-types →
- DDOST-congenital disorder of glycosylation 0 trials
- DPAGT1-congenital disorder of glycosylation 0 trials
- MAN1B1-congenital disorder of glycosylation 0 trials
- MGAT2-congenital disorder of glycosylation 0 trials
- MOGS-congenital disorder of glycosylation 0 trials
- RFT1-congenital disorder of glycosylation 0 trials
- SLC39A8-CDG 0 trials
- SSR4-congenital disorder of glycosylation 0 trials
- ST3GAL3-congenital disorder of glycosylation 0 trials Sub-types →
- STT3A-congenital disorder of glycosylation 0 trials
- STT3B-congenital disorder of glycosylation 0 trials
- TMEM165-congenital disorder of glycosylation 0 trials
- Autism spectrum disorder - epilepsy - arthrogryposis syndrome 0 trials
- Congenital disorder of glycosylation type 1EE with or without immunodeficiency 0 trials
- Developmental and epileptic encephalopathy, 36 0 trials
Most studied deeper sub-types
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for rare disease: experimental drug targets PMM2-CDG
Disease control CompletedThis study tested an experimental drug called GLM101 in 27 people with PMM2-CDG, a rare genetic condition that causes problems with balance and movement. Participants received different doses of the drug intravenously over 24 weeks. The main goal was to see if the drug improves c…
Phase 2 • Sponsor: Glycomine, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Researchers track rare disease PMM2-CDG to unlock clues for future treatments
Knowledge-focused CompletedThis study is gathering medical information from 120 people with PMM2-CDG, a rare genetic disorder. Researchers will track growth, organ function, and development over time. The goal is to better understand the disease and help design future treatments. No new drugs are being tes…
Sponsor: Glycomine, Inc. • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
New study tracks muscle decline in rare disease to guide future treatments
Knowledge-focused CompletedThis study followed 52 people with limb-girdle muscular dystrophy 2I (LGMD2I) for up to two years to learn more about how the disease changes over time. Researchers measured walking ability, muscle strength, heart function, and daily activities. The goal was to better understand …
Sponsor: Genethon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC